SAN DIEGO, Nov. 1, 2016 /PRNewswire/ -- OncoSec Medical
Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that
members of its leadership team will be making presentations at two high-profile events in November: 31st Annual Meeting &
Associated Programs of the Society for Immunotherapy of Cancer ("SITC") and the Stifel Nicolaus Weisel Healthcare Conference
2016.
31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Dr. Alain Algazi, Clinical Instructor, Department of Medicine (Hematology/Oncology) at
the University of California San Francisco (UCSF), will present an oral poster presentation for
Abstract #466 on November 11, 2016 at 12:50 PM (EST) in National
Harbor, MD. The title of the poster is "Phase II Study of Intratumoral Plasmid Interleukin 12 (pIL-12) with Electroporation in
Combination with Pembrolizumab in Stage III/IV Melanoma Patients with Low Tumor Infiltrating Lymphocytes." The SITC conference
brings together leading scientists, academicians, researchers, clinicians, government representatives, and industry leaders from
around the world that are dedicated to improving cancer patient outcomes by advancing the science and application of cancer
immunotherapy. For more information, please visit: http://www.sitcancer.org/2016.
Dr. Algazi, the Principal Investigator for the Phase II Investigator Sponsored Trial (IST) led by UCSF, will be presenting new
clinical data from patients treated with a combination of OncoSec's investigational intratumoral therapy,
ImmunoPulse® IL-12, and Merck's KEYTRUDA® (pembrolizumab). Patients who had unresectable
metastatic melanoma and were assessed as unlikely to respond to anti-PD1 monotherapy, were selected to participate in the
Investigator Sponsored Trial (IST). This oral poster presentation will provide an interim update of 15 treated patients. Further
details on this SITC oral poster presentation will be provided in upcoming Company communications.
Stifel Nicolaus Weisel Healthcare Conference 2016
OncoSec's CEO, Mr. Punit Dhillon, will present a corporate overview at the Stifel
Conference on November 15, 2016, at 11:00 AM EST, in New York
City. This conference provides a forum for institutional investors to connect with senior management and industry experts,
and serves as a showcase for dynamic emerging companies in the healthcare industry. For more information, please visit: http://www.stifel.com/institutional/ConferenceAndEvents.
To view the live webcast, please use the following link: http://wsw.com/webcast/stifel5/oncs. An archived version of the webcast will be available for 90 days on OncoSec's
website: http://www.oncosec.com.
OncoSec Investor & Analyst Day
In addition, OncoSec recently announced that it will be hosting its
inaugural Investor & Analyst Day in San Diego, on November 17,
2016. The event will be webcast live beginning at 8:00 AM PST. The live webcast can be
accessed at: http://edge.media-server.com/m/p/i6ug66hu, and will be available for replay on the Company website.
This event will provide a forum for the Company to share updates on its clinical development plan for melanoma, advancement of
its intratumoral immunotherapy pipeline of DNA-based product candidates, and next generation device development. For more
information, please visit: http://ir.oncosec.com/press-releases/detail/1883/oncosec-to-host-investor-analyst-day-on-november-17-2016
About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational
technology, ImmunoPulse®, for the treatment of cancer. ImmunoPulse® is designed to enhance the local delivery and uptake of
DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse® IL-12 has demonstrated a
favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors as well as the potential to
initiate a systemic immune response. OncoSec's lead program, ImmunoPulse® IL-12, is currently in clinical development for several
indications, including metastatic melanoma, head and neck cancer, and triple-negative breast cancer. The program's current focus
is on the significant unmet medical need in patients with melanoma who are refractory or non-responsive to anti-PD-1/PD-L1
therapies. In addition to ImmunoPulse® IL-12, the Company is also identifying and developing new immune-targeting agents for use
with the ImmunoPulse® platform. For more information, please visit www.oncosec.com.
CONTACT:
Sophia Ononye, PhD MPH MBA
Associate Director, Investor Relations and Corporate Communications
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
Logo - http://photos.prnewswire.com/prnh/20120905/LA68078LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oncosec-to-present-at-scientific-and-investment-conferences-and-to-host-inaugural-investor-and-analyst-day-in-november-300354589.html
SOURCE OncoSec Medical Incorporated